Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 92

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 2
Chunk 92
---
 -   42,376   -   35,098 Reversal of expected credit losses  -   94,912   -   842,401 Others  10,919   136,312   18,669   84,831 TOTAL OTHER INCOME  74,565   334,076   98,830   1,298,649                  OPERATING EXPENSES                Sales and marketing  (86,275)  (1,577,214)  (78,741)  (1,419,201)Research and development  (39,572)  -   (30,115)  - General and administrative  (261,005)  (492,464)  (366,906)  (427,829)Fair value loss on investments in equity securities  -   (119,499)  -   (179,433)Provision for expected credit losses   -   (215,942)  -   (122,843)TOTAL OPERATING EXPENSES  (386,852)  (2,405,119)  (475,762)  (2,149,306)                 (LOSS)/PROFIT FROM OPERATIONS  (305,980)  (988,150)  (372,431)  125,129                  FINANCE COSTS  (9,752)  (6,266)  (8,360)  (6,848)                 (LOSS)/PROFIT BEFORE TAX $(315,732) $(994,416)  (380,791)  118,281                  Tax expense  -   -   -   (77,207)                 NET (LOSS)/PROFIT ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(315,732) $(994,416) $(380,791) $41,074 

 41Table of Contents

Revenue. For the current nine month period ended September 30, 2025, we had total revenue of $6,941,151, compared to total revenue of $6,986,791 for the same period in the previous year. This represents